Sage Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
47.00
51.00
115.00
281.00
531.00
-
Gross Income
47.00
51.00
115.00
281.00
531.00
-
SG&A Expense
18,232.00
33,759.00
94,535.00
159,882.00
272,624.00
482,368
EBIT
18,279.00
33,810.00
94,650.00
160,163.00
273,155.00
393,238
Non Operating Income/Expense
3.00
9.00
23.00
35.00
64.00
22
Pretax Income
18,281.00
33,811.00
94,495.00
158,987.00
270,120.00
372,882
Consolidated Net Income
18,288.00
33,811.00
94,495.00
158,987.00
270,120.00
372,882
Net Income
18,288.00
33,811.00
94,495.00
158,987.00
270,120.00
372,882
Net Income After Extraordinaries
18,288.00
33,811.00
94,495.00
158,987.00
270,120.00
372,882
Net Income Available to Common
18,288.00
36,105.00
94,495.00
158,987.00
270,120.00
372,882
EPS (Basic)
0.61
1.67
3.40
4.75
7.09
8.08
Basic Shares Outstanding
29,970.60
21,574.30
27,778.30
33,492.80
38,113.70
46,121.20
EPS (Diluted)
0.61
1.67
3.40
4.75
7.09
8.08
Diluted Shares Outstanding
29,970.60
21,574.30
27,778.30
33,492.80
38,113.70
46,121.20
EBITDA
18,232.00
33,759.00
94,535.00
159,882.00
272,624.00
392,095
Non-Operating Interest Income
1.00
8.00
178.00
1,211.00
3,099.00
20,334
Other After Tax Income (Expense)
7.00
-
-
-
-
-
Preferred Dividends
-
2,294.00
-
-
-
-
About Sage Therapeutics
View Profile
